CELL-PENETRATING PEPTIDE FUSION PROTEINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 396

105. Mie M, Takahashi F, Funabashi H, Yanagida Y, Aizawa M,
Kobatake E. (2003) Intracellular delivery of antibodies using
TAT fusion protein A. Biochem. Biophys. Res. Commun. 310,
730-734.
106. Heng B, Cao T. (2005) Making cell-permeable antibodies
(Transbody) through fusion of protein transduction domains
(PTD) with single chain variable fragment (scFv) antibodies:
potential advantages over antibodies expressed within the
intracellular environment (Intrabody). Med. Hypotheses 64,
1105-1108.
107. CDG-Therapeutics. P28. Available at http://www.cdgti.com/.
Accessed 2010 Dec 20.
108. Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M,
Dubois V, et al. (2008) DTS-108, a novel peptidic prodrug of
SN38: in vivo efficacy and toxicokinetic studies. Clin. Cancer
Res. 14, 2145-2153.
109. Harada H, Hiraoka M, Kizaka-Kondoh S. (2002) Antitumor
effect of TAT-oxygen-dependent degradation-caspase-3
fusion protein specifically stabilized and activated in hypoxic
tumor cells. Cancer Res . 62, 2013-2018.
110. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K,
Inoue M, et al. (2007) Significance of HIF-1-active cells in
angiogenesis and radioresistance. Oncogene 26, 7508-7516.
111. Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T,
Takahashi Y, et al. (2009) Selective killing of hypoxia-induc-
ible factor-1-active cells improves survival in a mouse model
of invasive and metastatic pancreatic cancer. Clin. Cancer
Res. 15, 3433-3441.
112. Traversa-Therapeutics. CPP-DRBD siRNA. Available at
http://www.traversathera.com/. Accessed 2010 Dec 20.
113. Justesen S, Buus S, Claesson M, Pedersen A. (2007) Addition
of TAT protein transduction domain and GrpE to human p53
provides soluble fusion proteins that can be transduced into
dendritic cells and elicit p53-specific T-cell responses in
HLA-A 0201 transgenic mice. Immunology 122, 326-334.
114. Inagaki K, Begley R, Ikeno F, Mochly-Rosen D. (2005)
Cardioprotection by epsilon-protein kinase C activation
from ischemia: continuous delivery and antiarrhythmic effect
of an epsilon-protein kinase C-activating peptide. Circulation
111, 44-50.
115. Chen L, Harrison S. (2007) Cell-penetrating peptides in drug
development: enabling intracellular targets. Biochem. Soc.
Trans. 35, 821-825.
116. Price V. (2003) Therapy of alopecia areata: on the cusp and in
the future. J. Investig. Dermatol. Symp. Proc. 8, 207-211.
117. Delcroix M, Riley LW. (2010) Cell-penetrating peptides for
antiviral drug development. Pharmaceuticals 3(3), 448-470.
118. Lopes LB, Brophy CM, Furnish E, Flynn CR, Sparks O,
Komalavilas P, et al. (2005) Comparative study of the skin
penetration of protein transduction domains and a conjugated
peptide. Pharm. Res. 22, 750-757.
119. Lopes LB, Furnish E, Komalavilas P, Flynn C, Ashby P,
Hansen A, et al. (2009) Cell permeant peptide analogues of
the small heat shock protein, HSP20, reduce TGF-beta1-
induced CTGF expression in keloid fibroblasts. J. Invest.
Dermatol. 129, 590-598.

120. Hassane FS, Saleh AF, Abes R, Gait MJ, Lebleu B. (2010)
Cell penetrating peptides: overview and applications to the
delivery of oligonucleotides. Cell. Mol. Life Sci. 67, 715-726.
121. Moulton H, Moulton J. (2010) Morpholinos and their peptide
conjugates: therapeutic promise and challenge for Duchenne
muscular dystrophy. Biochim. Biophys. Acta. 1798, 2296-
2303.
122. J € arver P, Langel

€ U. (2004) The use of cell-
penetrating peptides as a tool for gene regulation. Drug
Discov. Today 9, 395-402.
123. KAI-Pharmaceuticals. KAI-9803. Available at http://www
.kaipharma.com/. Accessed 2010 Dec 20.
124. Revance-Therapeutics. RT001. Available at http://www
.revance.com/. Accessed 2010 Dec 20.
125. Avi-BioPharma. AVI-5126. Available at http://www.avibio
.com/. Accessed 2010 Dec 20.
126. Capstone-Therapeutics. AZX100. Available at http://www
.capstonethx.com/. Accessed 2010 Dec 20.
127. Xigen. AM-111. Available at http://www.xigen.ch/. Accessed
2010 Dec 20.
128. Auris-Medical. AM-111. Available at http://www.aurismedical
.com/. Accessed 2010 Dec 20.
129. Beckham J, Goody R, Clarke P, Bonny C, Tyler K. (2007)
Novel strategy for treatment of viral central nervous system
infection by using a cell-permeating inhibitor of c-Jun N-
terminal kinase. J. Virol. 81, 6984-6992.
130. Eshraghi A, Wang J, Adil E, He J, Zine A, Bublik M, et al.
(2007) Blocking c-Jun-N-terminal kinase signaling can pre-
vent hearing loss induced by both electrode insertion trauma
and neomycin ototoxicity. Hear. Res. 226, 168-177.
131. Liu J, Zhao Y, Patzer A, Staak N, Boehm R, Deuschl G, et al.
(2010) The c-Jun N-terminal kinase (JNK) inhibitor XG-102
enhances the neuroprotection of hyperbaric oxygen after
cerebral ischaemia in adult rats. Neuropathol. Appl. Neuro-
biol. 36, 211-224.
132. Wang J, Van De Water TR, Bonny C, De Ribaupierre F, Puel
JL, Zine A. (2003) A peptide inhibitor of c-Jun N-terminal
kinase protects against both aminoglycoside and acoustic
trauma-induced auditory hair cell death and hearing loss.
J. Neurosci. 23, 8596-8607.
133. Drais-Pharmaceuticals. DTS-108. Available at http://www
.draispharma.com/. Accessed 2010 Dec 20.
134. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY.
(2009) Systemic in vivo distribution of activatable cell pene-
trating peptides is superior to that of cell penetrating peptides.
Integrative Biology 1, 371-381.
135. Olson E, Jiang T, Aguilera T, Nguyen Q, Ellies L, Scadeng M,
et al. (2010) Activatable cell penetrating peptides linked to
nanoparticles as dual probes for in vivo fluorescence and
MR imaging of proteases. Proc. Natl. Acad. Sci. USA 107,
4311-4316.
136. Rizk S, Luchniak A, Uysal S, Brawley C, Rock R, Kossiakoff
A. (2009) An engineered substance P variant for receptor-
mediated delivery of synthetic antibodies into tumor cells.
Proc. Natl. Acad. Sci. USA 106, 11011-11015.

€ U, Langel